Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Inflammation and Corticosteroid Responsiveness in Severe Asthma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Imperial College London.
Recruitment status was  Recruiting
Information provided by:
Imperial College London Identifier:
First received: September 12, 2005
Last updated: May 19, 2008
Last verified: May 2008

Some patients with mild asthma may develop severe asthma. It is not known what makes patients with mild asthma become severe, and we plan to find out why this happens. Patients with severe asthma may have a different type of inflammation in the airway tubes. Patients with severe asthma do not get as much benefit from taking steroid inhalers or tablets compared to asthma patients with mild disease. The study hypothesis is that the inflammation in severe asthma is such that it makes steroids less effective in treating asthma. We will find out what possible abnormalities there are in the blood cells and the bronchoalveolar macrophage cells in the lungs of patients with severe asthma compared to those with mild or moderate asthma.

Condition Intervention Phase
Drug: Prednisolone
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Inflammation and Corticosteroid Responsiveness in Severe Asthma

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Lung function FEV1 [ Time Frame: days ] [ Designated as safety issue: Yes ]
  • Suppression of monocyte activation and alveolar macrophage activation by dexamethasone ex-vivo [ Time Frame: Days ] [ Designated as safety issue: No ]
  • Effect of corticosteroids on release of cytokines from macrophages [ Time Frame: Once ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Exhaled NO [ Time Frame: Days ] [ Designated as safety issue: No ]
  • Biopsy eosinophils [ Time Frame: Once ] [ Designated as safety issue: No ]
  • Sputum eosinophils [ Time Frame: Once ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: August 2003
Estimated Study Completion Date: May 2008
Estimated Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Treatment with prednisolone
Drug: Prednisolone
40 mg per day for 2 weeks

  Show Detailed Description


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

The final diagnosis of severe asthma will be made according to the screening steps we have set up. The definition will require the presence of one or both major criteria (treatment with continuous or near continuous oral corticosteroids and/or requirement for treatment with high dose inhaled steroids) and two minor criteria.

Patients who do not fit the criteria of severe asthma will not be entered into the study.

Age 18-60; both sexes.

For the investigation of fiberoptic bronchoscopy, other additional inclusion criteria will be imposed:

  1. Post-bronchodilator FEV1 greater than 40% on the day of the bronchoscopy
  2. No evidence of an exacerbation of asthma within the past 4 weeks.
  3. Ability to cooperate with procedures
  4. Ability to give consent
  5. Current smokers, and ex-smokers with greater than 10 pack years history of smoking.

Exclusion criteria

Pregnancy or unreliable contraceptive measures in child-bearing woman. he bronchoscopist has determined the subject is clinically appropriate for bronchoscopy


Exclusion Criteria:


  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180661

Contact: Fan Chung, MD 44 2073528121

United Kingdom
Royal Brompton Hospital Recruiting
London, United Kingdom, SW3 6HP
Contact: Sally Meah    44 207 351 8051      
Sponsors and Collaborators
Imperial College London
Principal Investigator: Kian Fan Chung, MD Imperial College London
  More Information

Responsible Party: Kian Fan Chung, Imperial College Identifier: NCT00180661     History of Changes
Other Study ID Numbers: HL-69155
Study First Received: September 12, 2005
Last Updated: May 19, 2008
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
Severe asthma
corticosteroid responsiveness

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases processed this record on March 01, 2015